OUTSTANDING PRELIMINARY RESULTS OF A CLINICAL TRIAL TREATING MODERATE-TO-SEVERE COVID-19 PATIENTS, CONDUCTED BY AMORPHICAL, AN ISRAELI BIOTECHNOLOGY COMPANY.
Amorphical’s Novel COVID-19 Oral and Inhaled Amorphous Calcium Carbonate (ACC) Treatment Significantly Reduces the Risk of ICU Admission and Mortality in Interim Analysis of a Phase II Study Involving Patients Hospitalized with Moderate-to-Severe COVID-19. (NIH Clinical Trial Registration No. NCT04900337) Outstanding preliminary results were revealed in an interim analysis of an on-going Phase II clinical …